$DNAX DNA Brands Receives Trademark of Blockchain Based DNATags(TM) from USPTO
https://www.accesswire.com/641360/dna-brands-...from-uspto
FORT LAUDERDALE, FL / ACCESSWIRE / April 21, 2021 / Shreya Arora, Freelance Journalist, India
After an anticipated two month wait, DNA Brands Inc. (OTC
NAX) in collaboration with Santo Blockchain Labs (OTC: SANP), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted the trademark for DNATags™. This news comes as a delight ahead of the company's plans to expand DNATags™, through various marketing and social media outlets.
DNA Brands in collaboration with Santo Blockchain Labs, developed and signed a joint venture for this unique third party verified blockchain authentication technology, DNATags™.
Both companies aim to provide a remedy for the many fraudulent and counterfeit malpractices which are being carried out in the Pharmaceutical World on a daily basis. According to a report by the World Health Organization (WHO), "The US Food and Drug Administration estimates that more than 10 percent of medicines in circulation in both developed and developing countries are counterfeit." Therefore, it is crucial that the consumers have the opportunity and ability to verify for themselves, whether they are consuming authentic drugs or the counterfeits. Both companies Mantra in regards to DNATags™ is " Authenticate before you Medicate"
In case you are wondering the extent of the impact and the importance of such a technology which both companies intend to bring to various medicinal market places. Here is some data: According to a worldwide market survey published on Statista, "the total number of counterfeit incidents concerning pharmaceuticals worldwide has exponentially risen from 196 reported cases in 2002 to over 5000 in 2019 and is only rising higher."
On receiving this trademark and talking about the expansion plans, Adrian McKenzie, CEO of DNA Brands said, "We are pleased with this milestone and will now look forward to begin marketing to the vast counterfeit medicinal markets such as, but not limited to; Medicinal Marijuana, the CBD market, the counterfeit Covid-19 Black market and any other Medicinal market or opportunity that presents itself. This technology is not limited, it can be used in Any market."
In addition to address a question that management receives often; the common share structure is as follows:
5.9MM common shares issued and outstanding
3.5MM common shares owned by management (insiders)
2.5MM common shares in the float (public hands).
https://www.accesswire.com/641360/dna-brands-...from-uspto
FORT LAUDERDALE, FL / ACCESSWIRE / April 21, 2021 / Shreya Arora, Freelance Journalist, India
After an anticipated two month wait, DNA Brands Inc. (OTC
NAX) in collaboration with Santo Blockchain Labs (OTC: SANP), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted the trademark for DNATags™. This news comes as a delight ahead of the company's plans to expand DNATags™, through various marketing and social media outlets. DNA Brands in collaboration with Santo Blockchain Labs, developed and signed a joint venture for this unique third party verified blockchain authentication technology, DNATags™.
Both companies aim to provide a remedy for the many fraudulent and counterfeit malpractices which are being carried out in the Pharmaceutical World on a daily basis. According to a report by the World Health Organization (WHO), "The US Food and Drug Administration estimates that more than 10 percent of medicines in circulation in both developed and developing countries are counterfeit." Therefore, it is crucial that the consumers have the opportunity and ability to verify for themselves, whether they are consuming authentic drugs or the counterfeits. Both companies Mantra in regards to DNATags™ is " Authenticate before you Medicate"
In case you are wondering the extent of the impact and the importance of such a technology which both companies intend to bring to various medicinal market places. Here is some data: According to a worldwide market survey published on Statista, "the total number of counterfeit incidents concerning pharmaceuticals worldwide has exponentially risen from 196 reported cases in 2002 to over 5000 in 2019 and is only rising higher."
On receiving this trademark and talking about the expansion plans, Adrian McKenzie, CEO of DNA Brands said, "We are pleased with this milestone and will now look forward to begin marketing to the vast counterfeit medicinal markets such as, but not limited to; Medicinal Marijuana, the CBD market, the counterfeit Covid-19 Black market and any other Medicinal market or opportunity that presents itself. This technology is not limited, it can be used in Any market."
In addition to address a question that management receives often; the common share structure is as follows:
5.9MM common shares issued and outstanding
3.5MM common shares owned by management (insiders)
2.5MM common shares in the float (public hands).
